Related Experiment Video
Updated: Sep 3, 2025
Sexual Transmission of American Trypanosomes from Males and Females to Naive Mates
Published on: January 27, 2019
Call for Consensus in the Evaluation of Circulating Matrix Metalloproteinases in Chagas Disease
Norma Bautista-López1, Richard Schulz2
1Macdonald Campus, Institute of Parasitology, McGill University, Montreal, Quebec, Canada.
Insights
Chagas cardiomyopathy, a heart condition caused by Trypanosoma cruzi infection, lacks reliable biomarkers. Measuring matrix metalloproteinases (MMPs) shows promise, but inconsistent blood sample methods hinder comparable research.
Area of Science:
- Cardiology
- Infectious Diseases
- Biochemistry
Background:
- Chagas cardiomyopathy, a leading cause of heart failure in endemic regions, affects approximately 30% of Trypanosoma cruzi infected individuals.
- Currently, no widely accepted biomarker accurately reflects Chagas cardiomyopathy progression.
- Inflammation following T. cruzi infection may activate matrix metalloproteinases (MMPs), implicating them in cardiac damage.
Purpose of the Study:
- To highlight the potential of matrix metalloproteinases (MMPs) as diagnostic and prognostic indicators for Chagas cardiomyopathy.
- To discuss the critical need for standardized methodologies in evaluating MMPs in Chagas disease research.
Main Methods:
- This perspective reviews existing research on MMPs in Chagas cardiomyopathy.
- It analyzes the discrepancies arising from varied methods of MMP evaluation in serum versus plasma.
Main Results:
- Inconsistent data regarding MMP blood levels in Chagas patients exist due to differing evaluation methods (serum vs. plasma).
- Lack of consensus on MMP measurement techniques impedes reliable interpretation of results.
Conclusions:
- Standardizing blood sample preparation for MMP analysis is crucial for comparable and reliable research on Chagas cardiomyopathy biomarkers.
- Adoption of a universal standard will enhance the utility of MMPs as indicators of cardiac damage in Chagas patients.
Abstract:
Infection with the Trypanosoma cruzi parasite is endemic in parts of America. Approximately 30% of people infected develop Chagas cardiomyopathy, the most common cause of heart failure in these regions. No suitable biomarker that reflects the evolution of the disease has been widely accepted as of yet. There is substantial evidence, however, of a strong inflammatory reaction following infection with T. cruzi that could activate matrix metalloproteinases (MMPs). Emerging research suggests the involvement of MMPs in Chagas cardiomyopathy and there is a growing interest in measuring the blood levels of MMPs as diagnostic and/or prognostic indicators of heart damage in Chagas patients. This perspective discusses the lack of consensus on the best method for MMP evaluation. Some studies are based on MMP concentrations and activities in serum whereas others use plasma. We believe that these different methods of evaluation have led to incongruent and poorly comparable data on the blood levels of MMPs in Chagas patients. A standard for the preparation of blood samples needs to be adopted for the study of MMPs as markers of Chagas cardiomyopathy to ensure better comparability of research results.
